Tokyo, Japan & Basking Ridge, New Jersey | April 13, 2026
Daiichi Sankyo, in collaboration with Merck & Co., Inc., has announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the Biologics License Application (BLA) for ifinatamab deruxtecan (I-DXd), an investigational antibody-drug conjugate (ADC) targeting extensive-stage small cell lung cancer (ES-SCLC) in patients who have progressed after platinum-based chemotherapy. This designation underscores the potential of this therapy to address a critical unmet medical need in aggressive lung cancer, with a PDUFA decision date set for October 10, 2026, signaling accelerated regulatory evaluation and potential faster patient access.
Priority Review Highlights Strong Clinical Efficacy Signals
The FDA’s decision is based on results from the IDeate-Lung01 Phase 2 clinical trial, supported by data from the IDeate-PanTumor01 Phase 1/2 study, demonstrating promising efficacy and safety outcomes. The therapy is designed as a first-in-class B7-H3 directed ADC, leveraging Daiichi Sankyo’s proprietary DXd technology platform to deliver a potent cytotoxic payload directly to tumor cells.
Priority Review is granted to therapies that demonstrate the potential for significant improvement over existing treatment options, reinforcing the clinical importance of ifinatamab deruxtecan in a disease setting where survival rates remain low and treatment options are limited.
Favorable Safety Profile Supports Outpatient CAR T Delivery
Advertisement
In addition to efficacy, cema-cel demonstrated a highly favorable safety profile, addressing one of the key limitations of traditional CAR T therapies. Notably, there were no reported cases of cytokine release syndrome (CRS), neurotoxicity (ICANS), or graft-versus-host disease (GvHD), which are commonly associated with CAR T treatments. Furthermore, no treatment-related serious adverse events or hospitalizations were observed, with the majority of patients managed entirely in an outpatient setting.
These findings suggest that cema-cel could enable safer, more accessible CAR T administration, potentially expanding its use beyond specialized centers into broader clinical settings, including community oncology practices.
Innovative ADC Technology Targets Unmet Oncology Needs
Ifinatamab deruxtecan represents a next-generation advancement in precision oncology, targeting the B7-H3 protein, which is highly expressed across multiple tumor types and associated with poor prognosis. The ADC combines a monoclonal antibody with a topoisomerase I inhibitor payload (DXd), enabling targeted delivery and enhanced anti-tumor activity while minimizing systemic toxicity. Notably, there are currently no approved B7-H3 targeted therapies, positioning this drug as a potential first-in-class treatment. The ongoing clinical development program includes multiple Phase 3 trials across various cancers, highlighting its broad therapeutic potential and strategic importance in oncology pipelines.
Regulatory Acceleration Through RTOR and Project Orbis
In addition to Priority Review, the application is being evaluated under the FDA’s Real-Time Oncology Review (RTOR) and Project Orbis initiatives, which are designed to expedite global regulatory approvals and improve patient access to innovative cancer therapies. RTOR allows early submission of clinical data, enabling faster review timelines, while Project Orbis facilitates simultaneous international regulatory collaboration.
These pathways reflect a growing emphasis on regulatory innovation and global harmonization, particularly for high-impact oncology treatments. The combined use of these programs demonstrates the urgency and importance of advancing new therapies for aggressive cancers such as ES-SCLC.
Clinical Need and Future Outlook in Small Cell Lung Cancer
Small cell lung cancer remains one of the most aggressive and rapidly progressing cancers, with approximately 250,000 cases diagnosed globally each year and limited survival outcomes, particularly in advanced stages. Despite existing treatments, patients who relapse after first-line therapy face significant therapeutic challenges, emphasizing the need for new approaches. Ifinatamab deruxtecan’s targeted mechanism and encouraging clinical data suggest it could transform treatment paradigms, offering improved outcomes for patients with limited options. Ongoing and future studies will further define its role in earlier lines of therapy and combination regimens, potentially expanding its clinical impact.
The FDA Priority Review of ifinatamab deruxtecan marks a critical milestone in the development of next-generation ADC therapies, combining clinical innovation, regulatory acceleration, and precision targeting. With strong supporting data and a clear unmet medical need, this therapy has the potential to become a first-in-class treatment for ES-SCLC, advancing the standard of care in oncology. As regulatory review progresses, the outcome could significantly influence future cancer treatment strategies and global drug development pathways.
Source: Daiichi Sankyo, Merck press release
